Market Research

Immunotherapy Drugs Market (Drug Type: Monoclonal Antibodies, Immunomodulators, Cell Therapy and Others; and Therapy Area: Cancer, Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 168 Pages Transparency Market Research Pvt. Ltd. January, 2024 TNPR18580364
Best Price Guarantee
Price from $5,795
Length 168 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2024
SKU TNPR18580364

Immunotherapy Drugs Market (Drug Type: Monoclonal Antibodies, Immunomodulators, Cell Therapy and Others; and Therapy Area: Cancer, Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Immunotherapy Drugs Market – Scope of Report

TMR’s report on the global immunotherapy drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global immunotherapy drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global immunotherapy drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the immunotherapy drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global immunotherapy drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global immunotherapy drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global immunotherapy drugs market.

The report delves into the competitive landscape of the global immunotherapy drugs market. Key players operating in the global immunotherapy drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global immunotherapy drugs market profiled in this report.

Key Questions Answered in Global immunotherapy drugs Market Report
  • What is the sales/revenue generated by immunotherapy drugs across all regions during the forecast period?
  • What are the opportunities in the global immunotherapy drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Immunotherapy Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global immunotherapy drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global immunotherapy drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global immunotherapy drugs market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Immunotherapy Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Global Immunotherapy Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. COVID-19 Impact Analysis
6. Global Immunotherapy Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Immunomodulators
6.3.3. Cell Therapy
6.3.4. Others (Vaccines, etc.)
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Immunotherapy Drugs Market Analysis and Forecast, by Therapy Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapy Area, 2017–2031
7.3.1. Cancer
7.3.2. Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Area
8. Global Immunotherapy Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Online Pharmacies
8.3.3. Hospital Pharmacies
9. Global Immunotherapy Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Immunotherapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Immunomodulators
10.2.3. Cell Therapy
10.2.4. Others (Vaccines, etc.)
10.3. Market Value Forecast, by Therapy Area, 2017–2031
10.3.1. Cancer
10.3.2. Autoimmune Diseases
10.3.3. Infectious Diseases
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Online Pharmacies
10.4.3. Hospital Pharmacies
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Therapy Area
10.5.3. By Distribution Channel
10.5.4. By Country
11. Europe Immunotherapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Immunomodulators
11.2.3. Cell Therapy
11.2.4. Others (Vaccines, etc.)
11.3. Market Value Forecast, by Therapy Area, 2017–2031
11.3.1. Cancer
11.3.2. Autoimmune Diseases
11.3.3. Infectious Diseases
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Online Pharmacies
11.4.3. Hospital Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Therapy Area
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Immunomodulators
12.2.3. Cell Therapy
12.2.4. Others (Vaccines, etc.)
12.3. Market Value Forecast, by Therapy Area, 2017–2031
12.3.1. Cancer
12.3.2. Autoimmune Diseases
12.3.3. Infectious Diseases
12.3.4. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Online Pharmacies
12.4.3. Hospital Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Therapy Area
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Immunotherapy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Immunomodulators
13.2.3. Cell Therapy
13.2.4. Others (Vaccines, etc.)
13.3. Market Value Forecast, by Therapy Area, 2017–2031
13.3.1. Cancer
13.3.2. Autoimmune Diseases
13.3.3. Infectious Diseases
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Online Pharmacies
13.4.3. Hospital Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Therapy Area
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Immunomodulators
14.2.3. Cell Therapy
14.2.4. Others (Vaccines, etc.)
14.3. Market Value Forecast, by Therapy Area, 2017–2031
14.3.1. Cancer
14.3.2. Autoimmune Diseases
14.3.3. Infectious Diseases
14.3.4. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Online Pharmacies
14.4.3. Hospital Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Therapy Area
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Immunotherapy Drugs Market, Company Share Analysis (2022)
15.2. Company Profiles
15.2.1. Bristol Myers Squibb
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Merck KGaA, Inc.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Novartis AG
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Pfizer
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Amgen
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Regeneron Pharmaceuticals Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. F. Hoffmann-La Roche AG
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. Eli Lilly and Company
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings